Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Clinical trial NCT02989714 · COMPLETED
Trial details
- NCT number
- NCT02989714
- Sponsor
- University of Michigan Rogel Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-16
- Primary completion
- 2019-02-25
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.